A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Phase of Trial: Phase II
Latest Information Update: 03 Oct 2017
At a glance
- Drugs BMS 986165 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 13 Sep 2017 Planned End Date changed from 8 Apr 2020 to 29 Apr 2020.
- 13 Sep 2017 Planned primary completion date changed from 18 Mar 2020 to 8 Apr 2020.
- 13 Sep 2017 Status changed from not yet recruiting to recruiting.